iMmune SignAtures and Clinical outComes in AP

Study acronym: MoSAIC
StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion pushed from Dec 31, 2027 to Dec 31, 2028
    • Eligibility criteria expanded, about 13 words
    • Study description revised
    • Site contacts updated at 1 of 5 sites
  2. Re-verified, no change to tracked fieldsv3
  3. Site contacts updated at 2 of 5 sitesv2
  4. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The MoSAIC study is a prospective, observational study designed to develop an early prediction tool for severe acute pancreatitis (SAP) and define a distinct immunologic profile compared to moderate acute pancreatitis (MAP). The aims are to validate a new multi-cytokine panel for early prediction of SAP and to identify the specific immune cells that correspond with cytokine signatures in early acute pancreatitis to characterize the immune pathways driving the development of SAP. Participants will provide blood samples and complete patient surveys and interviews within 36 hours of hospital presentation, at 48 hours, and hospital day 7 (if admitted). Data on hospital stay, medical history, clinical course, and severity of disease will be collected.
Trial Details
NCT Number NCT05878236
Lead Sponsor Ohio State University
Collaborators: University of Pittsburgh, University of Illinois at Chicago, University of Southern California, Benaroya Research Institute
Conditions
(from sponsor)		 Acute Pancreatitis
Related terms Pancreatitis
Enrollment 198 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov